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The	   objective	   of	   this	   study	   was	   to	   estimate	   the	   direct	   financial	   costs	   of	   hospital	   care	   for	  
management	  of	  invasive	  group	  A	  streptococcal	  infections	  using	  hospital	  records	  for	  cases	  diagnosed	  
in	  England.	  We	  linked	  laboratory-­‐confirmed	  cases	  (n=3,696)	  identified	  through	  national	  surveillance	  
to	  hospital	  episode	  statistics	  and	  reimbursement	  codes.	  From	  these	  codes	  we	  estimated	  the	  direct	  
hospital	  costs	  of	  admissions.	  Almost	  all	  notified	  invasive	  GAS	  cases	  (92%	  of	  3696)	  were	  successfully	  
matched	  to	  a	  primary	  hospital	  admission.	  Of	  these,	  secondary	  admissions	  (within	  30	  days	  of	  primary	  
admission)	   were	   further	   identified	   for	   593	   (17%).	   After	   exclusion	   of	   nosocomial	   cases	   (12%),	   the	  
median	  costs	  of	  primary	  and	  secondary	  hospital	  admissions	  were	  estimated	  by	  subgroup	  analysis	  as	  
£1984	   –	   £2212	  per	   case,	   totalling	   £4.43	   –	   £6.34	  million	   per	   year	   in	   England.	  With	   adjustment	   for	  
unmatched	  cases	  this	  equated	  to	  £4.84	  –	  £6.93	  million	  per	  year.	  Adults	  aged	  16–64	  years	  accounted	  
for	  48%	  of	  costs	  but	  only	  40%	  of	  cases,	   largely	  due	  to	  an	  increased	  number	  of	  surgical	  procedures.	  
The	  direct	   costs	  of	  hospital	  admissions	   for	   invasive	  GAS	   infection	  are	   substantial.	   These	  estimated	  
costs	  will	  contribute	  to	  a	  full	  assessment	  of	  the	  total	  economic	  burden	  of	  invasive	  GAS	  infection	  as	  a	  





Group	   A	   streptococcal	   (GAS)	   infection	   causes	   a	   diverse	   range	   of	   diseases	   from	   common,	   mild	  
complaints	  such	  as	  pharyngitis,	  to	  severe	  conditions,	  such	  as	  necrotising	  fasciitis	  [1].	  While	  invasive	  
GAS	  infections	  (Streptococcus	  pyogenes	  isolated	  from	  a	  normally	  sterile	  site)	  are	  uncommon,	  around	  
three	   per	   100,000	   persons	   in	   the	   UK	   and	   other	   developed	   countries	   [2,	   3],	   most	   result	   in	  
hospitalisation	   [4–6]	   and	   around	   one	   fifth	   will	   require	   critical	   care	   [2,	   6].	   Mortality	   is	   very	   high,	  
estimated	  at	  16%	  at	  7	  days	  post-­‐diagnosis	   [7].	  Although	   risk	   factors	   for	   invasive	  GAS	   infection	  are	  
well	   established	   [8],	   in	   approximately	   a	   quarter	   of	   cases	   no	   risk	   factors	   are	   identified	   [2].	  
Asymptomatic	   carriers	   may	   be	   sources	   of	   GAS	   infection	   [1]	   and	   given	   that	   most	   cases	   occur	  
sporadically,	  opportunities	  for	  prevention	  are	  limited	  [8].	  As	  such,	  there	  is	  a	  clear	  need	  to	  develop	  a	  
safe	   and	   effective	   GAS	   vaccine	   [9].	   However,	   the	   diversity	   in	   serotypes	   [10],	   cross-­‐reaction	   of	  
antibodies	  with	  human	   tissues	   [11]	  and	   the	   lack	  of	   suitable	  animal	  models	   [12]	  have	  all	   restricted	  
vaccine	  development.	  	  
Invasive	  GAS	  infection	  accounts	  for	  only	  part	  of	  the	  global	  burden	  of	  GAS	  infections	  [1,	  13]	  yet	  given	  
the	   complex	   care	   needed	   for	   management	   of	   invasive	   GAS	   infections	   the	   financial	   costs	   of	  
hospitalisation	  may	   be	   considerable.	   An	   assessment	   of	   the	   full	   economic	   burden	  will	   be	   required	  
before	  considering	  the	  cost-­‐effectiveness	  of	  any	  vaccination	  programme.	  The	  societal	  costs	  of	  GAS	  
pharyngitis	   in	   an	   area	   of	   the	   US	   have	   been	   estimated	   to	   be	   $205	   per	   case	   [13]	   but	   the	   cost	   of	  
hospital	   admissions	   associated	   with	   invasive	   GAS	   infection	   are	   currently	   unknown.	   Methods	   to	  
estimate	  the	  cost	  of	  hospital	  admissions	  for	   infections	  can	  either	  utilise	  the	  actual	  billing	  cost	  [14–
16]	  or	  use	  unit	  costs	  based	  on	  either	   the	  type	  of	  admission	   [17,	  18]	  or	  a	  diagnosis	   resource	  group	  
[19–25].	  	  
As	   a	  means	   to	   assess	   the	   economic	   burden	   associated	  with	   hospital	   care	   for	   the	  management	   of	  
invasive	   GAS	   infection,	   we	   estimated	   the	   direct	   costs	   of	   hospital	   resources	   associated	   with	  
admissions	  for	  a	  three-­‐year	  period	  in	  England	  (2008-­‐2010).	  We	  used	  a	  case-­‐based	  methodology	  with	  
healthcare	  resource	  group	  codes	  derived	  from	  a	  national	  database	  of	  hospital	  admissions	  (Hospital	  
Episode	  Statistics;	  HES).	  These	  codes	  are	  used	  to	  reimburse	  for	  care	  provided	  to	  patients	  admitted	  to	  




Case	  definitions	  and	  ascertainment	  
Cases	  were	  defined	  by	  the	  isolation	  of	  GAS	  from	  a	  normally	  sterile	  site	  from	  clinical	  specimens	  taken	  
between	  1	  January	  2008	  and	  31	  December	  2010.	  Cases	  were	  identified	  through	  a	  national	  database	  
integrating	  routine	  laboratory	  surveillance	  reports	  and	  records	  of	  isolates	  submitted	  to	  the	  national	  
reference	   laboratory.	   For	   individuals	  with	  more	   than	   one	   specimen,	   the	   date	   of	   the	   earliest	  GAS-­‐
positive	  specimen	  was	  used.	  A	  nosocomial	  case	  was	  defined	  as	  one	  where	  the	  date	  of	  the	  positive	  
specimen	  was	  ≥2	  days	  after	  hospital	  admission.	  
Cases	  were	  linked	  to	  hospital	  admissions	  using	  their	  unique	  National	  Health	  Service	  (NHS)	  number.	  A	  
primary	   admission	   was	   defined	   as	   one	   where	   the	   GAS-­‐positive	   specimen	   was	   taken	   during	   the	  
admission	   or	   up	   to	   14	   days	   prior	   to	   the	   admission	   date	   (in	   order	   to	   include	   cases	  with	   a	   delayed	  
onset).	  A	   secondary	  admission	  was	  defined	  as	  a	   subsequent	  admission	  ≤30	  days	  after	   the	  primary	  
admission	  discharge.	  	  
Healthcare	  resource	  groups	  
In	   order	   to	   cost	   admissions,	   the	   ICD-­‐10	   primary	   diagnosis	   codes	   and	   the	   interventions	   and	  
procedures	   (Office	   of	   Population	   Censuses	   and	   Surveys	   classification	   of	   interventions	   and	  
procedures,	   version	   4;	   OPCS-­‐4)	   recorded	   for	   each	   case	   within	   HES	   were	   used	   to	   generate	   a	  
healthcare	   resource	   group	   casemix	   classification	   code	   (version	   4,	   HRG4)	   using	   the	   2010/11	   NHS	  
Local	  Payment	  Grouper	  (LPG;	  available	  from	  http://www.hscic.gov.uk).	  The	  LPG	  uses	  codes	  recorded	  
for	  a	  hospital	  admission	  and	  produces	  a	  single	  HRG4	  code	  for	  that	  admission.	  Where	  an	  admission	  
was	   followed	   by	   transfer(s)	   to	   another	   hospital,	   these	   admissions	   were	   combined	   to	   generate	   a	  
single	  HRG4	   code.	  HRG4	   codes	  were	   translated	   into	   reimbursement	   costs	  by	   referring	   to	   the	  NHS	  
national	  tariff	  for	  2010/11	  [26].	  Extended	  hospital	  stays	  not	  covered	  by	  the	  standard	  tariff	  (long	  stay	  
trim-­‐point)	  were	  identified	  and	  costs	  adjusted	  using	  the	  per	  diem	  for	  each	  code.	  
Cases	  with	  a	  primary	  hospital	  admission	  were	  divided	   into	  four	  groups	  to	  account	  for	  the	  differing	  
degree	  of	   certainty	   in	  attributing	   their	  hospital	   costs	  directly	   to	   invasive	  GAS	   infection.	  This	   group	  
allocation	  was	  based	  on	   the	  presence	  or	  absence	  of	   (1)	  diagnosis	   codes	   for	   invasive	  GAS	   infection	  
combined	  with	  the	  presence	  or	  absence	  of	  (2)	  a	  resource	  group	  code	  compatible	  with	  treatment	  for	  
an	  invasive	  GAS	  infection	  (creating	  four	  groups	  in	  total;	  Fig.	  1).	  For	  (1),	  ICD-­‐10	  diagnosis	  codes	  were	  
used	   based	   on	   those	   recorded	   which	   included	   mention	   of:	   abscess,	   cellulitis,	   empyema,	  
endocarditis,	   endometriosis,	   fasciitis,	   gangrene,	   infective	   arthritis,	   meningitis,	   myositis,	  
osteomyelitis,	  peritonitis,	  pneumonia,	  puerperal	   sepsis,	   sepsis,	   septicaemia,	   toxic	   shock	   syndrome,	  
unspecified	   streptococcal	   infection.	  We	   excluded	   ICD-­‐10	   codes	   that	   specified	   non-­‐GAS	   organisms.	  
For	   (2),	   we	   derived	   a	   list	   of	   HRG4	   codes	   that	   were	   associated	  with	   ICD-­‐10	   codes	   from	   (1)	   in	   the	  
2010/11	  NHS	  HRG4	  Code	  to	  Group	  workbook	  (v1.0)	  (available	  from	  http://www.hscic.gov.uk).	  
As	  a	  new	  LPG	  is	  released	  each	  year,	  we	  tested	  the	  suitability	  of	  using	  a	  single	  LPG	  for	  the	  three	  years	  
of	  study	  data	  by	  assessing	  the	  consistency	  of	  coding	  for	  primary	  diagnosis	  (ICD-­‐10),	  main	  operative	  
procedures	  (OPCS-­‐4)	  and	  resource	  group	  (HRG4)	  codes	  for	  all	  primary	  admissions.	  For	  this	  purpose	  
we	  compared	  only	  the	  distribution	  of	  codes	  that	  accounted	  for	  ≥1%	  of	  primary	  admissions	  during	  a	  
study	  year	  and	  where	   the	  code	  had	  a	  hierarchy	   level	  ≥3	   (thus	  excluding	   low	  resource	  expenditure	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procedures).	   Study	   groups	   were	   also	   created	   for	   three	   character	   OPCS-­‐4	   codes	   for	   the	   main	  
operation,	  excluding	  subsidiary	  classification	  codes	  (from	  OPCS-­‐4	  chapters	  Y	  and	  Z)	  from	  all	  primary	  
admissions	  not	  defined	  as	  nosocomial	  infections.	  
Costing	  critical	  care	  
As	  payments	   for	   critical	   care	   in	   the	  NHS	  are	   covered	  by	   separate	  arrangements	   to	  other	   costs	   for	  
admitted	   care,	   these	   are	   not	   reliably	   identified	   through	   HES.	   In	   recognition	   of	   this,	   the	   expected	  
frequency	  of	  critical	  care	  was	  determined	  using	  the	  available	  enhanced	  surveillance	  data	  for	  invasive	  
GAS	   in	   England,	   for	   2003/04	   and	   2009	   [2,	   27].	   HES	   data	   for	   Augmented	   Care	   Periods	   (ACP)	  were	  
available	   for	   cases	   with	   a	   hospital	   admission	   between	   April	   2008	   and	   March	   2009	   and	   used	   to	  
determine	  the	  number	  of	  organs	  supported	  during	  critical	  care	  and	  the	   length	  of	  stay	  on	   intensive	  
care	  or	  high	  dependency	  units.	  These	  were	  then	  used	  to	  cost	  critical	  care	  episodes	  according	  to	  NHS	  
benchmark	  costs	  for	  2010/11	  [28].	  
Sensitivity	  and	  age	  group	  analysis	  	  
A	   subgroup	   sensitivity	   analysis	  was	   undertaken	   in	   order	   to	   account	   for	   the	   inability	   to	   determine	  
those	  admissions	  with	  costs	  directly	  as	  a	  result	  of	  invasive	  GAS	  infection	  and	  uncertainty	  as	  to	  which	  
secondary	   admissions	   were	   truly	   a	   consequence	   of	   invasive	   GAS	   infection.	   Analysis	   of	   costs	   was	  
undertaken	  by	  age	  groups:	  children	  (≤15	  years),	  working	  age	  adults	  (16-­‐64	  years),	  older	  adults	  (≥65	  
years).	  
Statistical	  analysis	  
Comparison	   of	   continuous	   variables	   for	   independent	   groups	   was	   performed	   using	   the	   Mann-­‐




Linkage	  of	  cases	  to	  hospital	  admissions	  
Of	  the	  3696	  cases	  of	  invasive	  GAS	  infection	  identified	  through	  national	  surveillance	  in	  England	  during	  
2008–2010,	   3555	   (96%)	  were	   linked	   to	  ≥1	  hospital	   admission.	  Of	   these,	   3400	   (92%	  of	   total	   cases)	  
represented	  primary	  admissions,	  of	  which	  227	  involved	  transfers	  between	  hospitals	  and	  593	  (17%)	  
had	   ≥1	   secondary	   admission.	   The	   median	   interval	   between	   primary	   discharge	   and	   secondary	  
admission	  was	  9	  days	  (interquartile	  [IQR]	  range	  3–20).	  Of	  the	  3383	  primary	  admissions	  which	  could	  
ultimately	   be	   costed,	   391	   (11.6%)	   represented	   nosocomial	   infections.	  Of	   these,	   118	   (30%)	   had	   an	  
HRG4	  resource	  group	  code	  not	  included	  in	  our	  list	  of	  invasive	  GAS	  infection	  codes,	  suggesting	  costs	  
dominated	  by	  management	  of	  other	  conditions.	  	  
Clinical	  diagnoses	  
A	  wide	  array	  of	  ICD-­‐10	  diagnostic	  codes	  was	  associated	  with	  primary	  admissions,	  reflecting	  both	  the	  
spectrum	  of	  clinical	  presentations	  for	  invasive	  GAS	  infection	  and	  co-­‐morbidities	  (Supplementary	  Fig.	  
S1).	  Up	  to	  six	  primary	  diagnosis	  codes	  were	   indicated,	  although	  the	  majority	  of	  cases	  had	   just	  one	  
code	   (2761/3400,	  81.2%).	  Over	  half	   (1835/3400,	  54%)	  of	  primary	  admissions	  were	  associated	  with	  
an	  invasive	  GAS	  diagnosis	  code	  although	  only	  one	  code	  specifically	  mentioned	  GAS	  as	  the	  causative	  
organism	  (A40.0,	  “Sepsis	  due	  to	  streptococcus,	  group	  A”),	  recorded	  for	  12%	  (422/3400)	  of	  primary	  
admissions.	   The	   four	   highest	   frequency	   diagnosis	   groups	  were	   septicaemia	   (638,	   15.2%),	   skin	   and	  
soft	  tissue	  infection	  (540,	  12.9%),	  pneumonia	  (373,	  8.9%),	  and	  infective	  arthritis	  (212,	  5.1%).	  Of	  the	  
1756	  different	  ICD-­‐10	  diagnosis	  codes,	  117	  included	  a	  named	  condition	  consistent	  with	  invasive	  GAS	  
infection	   and	   of	   these	   93	   were	   used	   as	   indicators	   of	   admission	   for	   invasive	   GAS	   infection	  
(Supplementary	   Table	   1)	   and	   to	   identify	   48	   corresponding	   resource	   group	   codes	   (Supplementary	  
Table	  2)	  to	  define	  costing	  groups	  (Table	  1).	  
Although	  the	  diversity	  of	  diagnosis	  codes	  for	  secondary	  admissions	  was	  substantial	  (Supplementary	  
Fig.	  S2),	  288	  (28.9%)	  of	  these	  994	  diagnoses	  (after	  excluding	  those	  associated	  with	  nosocomial	  cases)	  
were	   from	   ICD-­‐10	   groups	   compatible	   with	   diagnosis	   of	   invasive	   GAS	   infection:	   septicaemia	   (42,	  
4.2%),	  skin	  and	  subcutaneous	  tissue	   infections	   (75,	  7.5%),	  pneumonia	   (42,	  4.2%),	   infective	  arthritis	  
(73,	  7.3%),	  other	  groups	  (56,	  5.6%).	  
Healthcare	  resource	  groups	  
All	  primary	  admissions	  were	  successfully	  assigned	  a	  resource	  group	  code.	  Diagnosis,	  procedure	  and	  
resultant	   resource	   group	   codes	   showed	   a	   general	   consistency	   of	   use	   over	   the	   study	   period	  
(Supplementary	   Fig.	   S3).	   HRG4	   resource	   group	   codes	   for	   primary	   admissions	  were	   predominantly	  
those	   for	   infectious	   diseases	   (502,	   14.8%),	   skin	   disorders	   (424,	   12.5%),	   thoracic	   procedures	   and	  
disorders	  (406,	  11.9%),	  and	  paediatric	  medicine	  (404,	  11.9%)	  (Supplementary	  Fig.	  S4).	  The	  paediatric	  
medicine	   subchapter	   contains	   clinical	   codes	   for	   care	   of	   all	   children	   ≤18	   years;	   of	   the	   404	   primary	  
admissions	  with	  resource	  group	  codes	  within	  this	  subchapter,	  >75%	  were	  associated	  with	  codes	  for	  




Costs	  of	  hospital	  admissions	  
The	  costing	  groups	  used	  in	  this	  study	  separate	  cases	  based	  on	  diagnosis	  and	  treatment	  codes	  (Table	  
1),	  with	  clear	  differences	   in	  hospital	  admission	  costs	  and	   length	  of	  stay	  after	  removing	  nosocomial	  
cases	   (Fig.	   2).	   The	   highest	   proportion	   of	   cases	   fell	   within	   costing	   group	   I	   (1250,	   34%	   of	   all	   cases;	  
Table	   2),	   characterised	   by	   both	   diagnosis	   and	   treatment	   compatible	   with	   invasive	   GAS	   infection.	  
Median	   costs	   of	   hospital	   care	   (entire	   stay,	   excluding	   critical	   care)	  were	   £1707	   for	   these	   patients.	  
Costing	  group	  II,	  cases	  without	  invasive	  GAS	  clinical	  diagnosis	  codes	  but	  whose	  care	  was	  compatible	  
with	   management	   of	   invasive	   GAS	   infection,	   had	   shorter	   admissions	   (median	   5	   days;	   Fig.	   2)	   and	  
lower	   in-­‐hospital	  mortality	   rates	   (7%;	  Table	  1).	  Conversely,	  costing	  group	   III,	  patients	  with	   invasive	  
GAS	   clinical	   diagnosis	   codes	   but	   without	   resource	   codes	   directly	   attributable	   to	   invasive	   GAS	  
infection	  (e.g.	  non-­‐trauma	  related	  procedures),	  had	  substantially	  longer	  admissions	  (median	  17	  days;	  
Fig.	  2)	  and	  high	  costs	  (median	  £3108,	  excluding	  critical	  care;	  Fig.	  2).	  Costing	  group	  IV	  represent	  cases	  
with	  neither	  an	  invasive	  GAS	  diagnosis	  code	  nor	  an	  invasive	  GAS	  resource	  group	  code	  and	  contained	  
the	  highest	  proportion	  of	  nosocomial	  cases	  for	  any	  costing	  group	  (Table	  2).	  	  
Invasive	  GAS	  cases	  which	  died	  in	  hospital	  had	  reduced	  lengths	  of	  admission	  and	  costs,	  although	  this	  
was	  not	  statistically	  significant	  for	  costing	  groups	   II	  and	  IV	  (Table	  3).	  The	  proportion	  of	  nosocomial	  
cases	  was	  significantly	  higher	  for	  costing	  groups	  where	  diagnosis	  of	  invasive	  GAS	  infection	  could	  not	  
be	   determined	   from	   HES	   (costing	   groups	   I	   &	   III:	   7.8%	   (130/1835);	   costing	   groups	   II	   &	   IV:	   17.4%	  
(273/1565);	  χ2	  =	  86.76,	  P<0.0001).	  The	  median	  length	  of	  critical	  care	  stay	  for	  the	  small	  proportion	  of	  
cases	   where	   this	   could	   be	   determined	   (184,	   5.4%)	  was	   4	   days	   (IQR:	   1–10).	   ACP	   data	   identified	   a	  
median	  of	  three	  organs	  supported	  during	  critical	  care	  (pragmatically	  assumed	  to	  be	  constant	  during	  
a	  critical	  care	  stay),	  translating	  to	  £1386	  per	  bed-­‐day.	  For	  total	  cost	  estimates,	  we	  adjusted	  HES	  costs	  
using	  external	  validation	  of	  the	  likely	  frequency	  of	  critical	  care	  (20%	  of	  cases).	  	  
After	   producing	   cost	   estimates	   for	   secondary	   admissions	   (Table	   4),	   subgroup	   sensitivity	   analysis	  
estimated	  the	  cost	  of	  hospital	  resources	  for	  invasive	  GAS	  infections	  to	  be	  £4.43	  –	  £6.34	  million	  per	  
year	  in	  England	  (Table	  5).	  After	  adjusting	  for	  cases	  which	  could	  not	  be	  linked	  to	  a	  hospital	  admission,	  
these	   costs	   are	  £4.84	  –	  £6.93	  million	  per	   year	   in	   England.	   The	  median	   cost	  per	   case	  was	  £1984	  –	  
£2212,	  with	  substantial	  variation	  in	  the	  cost	  of	  individual	  admissions	  (£247	  –	  £358,100).	  Costs	  by	  age	  
group	  were	  largely	  consistent	  with	  the	  distribution	  of	  cases,	  although	  the	  expected	  fraction	  of	  costs	  
for	  working	  age	  adults	  (16-­‐64	  years)	  was	  slightly	  higher,	  while	  that	  for	  children	  (≤15	  years)	  and	  older	  
adults	   (≥65	   years)	   reduced	   (Table	   6).	   This	   would	   appear	   to	   be	   due	   to	   an	   increased	   number	   of	  
operations	   (particularly	   abdominal,	   chest,	   skin	   and	   soft	   tissue	   surgeries),	   procedures	   related	   to	  
pregnancy,	  and	  higher	  numbers	  of	   cases	   requiring	  cardiovascular	  and	   respiratory	  care	   (Table	  7).	   It	  
was	  not	  accounted	  for	  by	  an	  increased	  length	  of	  stay	  for	  working	  age	  adults	  (median	  9	  days,	  IQR:	  4–





This	   study	   provides	   the	   first	   estimate	   of	   the	   cost	   of	   hospital	   care	   for	   invasive	   GAS	   infection.	   The	  
generation	   of	   these	   costs	   has	   included	   careful	   consideration	   of	   both	   the	   clinical	   nature	   of	   the	  
infection	  and	  the	  methodological	  approach	  to	  costing	  admissions	  using	  routinely	  collected	  hospital	  
admission	   data.	   With	   a	   study	   of	   this	   kind,	   a	   single	   point	   estimate	   of	   costs	   will	   be	   unlikely	   to	  
satisfactorily	   represent	   the	   full	   complexity	   of	   the	   analysis	   undertaken	   and	   the	   accompanying	  
uncertainty.	  With	   this	   in	  mind,	  we	   have	   estimated	   the	   cost	   of	   hospital	   resources	   associated	  with	  
admissions	  for	  treatment	  of	  invasive	  GAS	  infection	  to	  be	  £4.43	  –	  £6.34	  million	  per	  year	  in	  England.	  
This	  reflects	  uncertainty	  in	  directly	  attributing	  costs	  to	  treatment	  of	  invasive	  GAS	  infection	  for	  both	  
primary	   and	   secondary	   hospital	   admissions.	   Conservatively	   we	   have	   excluded	   all	   nosocomial	  
infections	  from	  our	  costing	  estimates.	  However,	  clinical	  management	  of	  invasive	  GAS	  infection	  may	  
have	  dominated	   the	   treatment	   costs	   for	   some	  of	   these	   cases	   and	   their	   removal	  will	   represent	   an	  
underestimate.	  We	  have	  also	  likely	  excluded	  some	  community-­‐acquired	  cases	  where	  there	  was	  late	  
diagnosis.	  Our	  estimate	  is	  for	  cases	  that	  we	  have	  been	  able	  to	  successfully	  link	  to	  a	  primary	  hospital	  
admission	   and	   could	   be	   8%	   higher	   (£4.84	   –	   £6.93	   million	   per	   year)	   if	   we	   failed	   to	   identify	  
corresponding	   hospital	   records	   for	   cases	   that	   were	   in	   fact	   treated	   within	   a	   hospital	   setting.	  
Published	   percentages	   of	   cases	   requiring	   hospitalisation	   range	   from	   98-­‐99%	   in	   Australia	   and	  New	  
Zealand	  [4,	  6]	  to	  91%	  in	  the	  United	  States	  [5].	  
The	  lower	  range	  of	  our	  estimated	  costs	  is	  based	  on	  cases	  with	  invasive	  GAS	  infection	  diagnosis	  codes	  
and/or	  invasive	  GAS	  infection	  healthcare	  resource	  group	  codes	  (for	  the	  associated	  primary	  hospital	  
admission).	   The	   exclusion	   of	   other	   cases	   was	  made	   to	   remove	   admissions	   which	  may	   have	   been	  
dominated	   by	   condition(s)	   independent	   to	   invasive	   GAS	   infection.	   However,	   this	   excludes	   a	  
substantial	   proportion	   of	   cases	   (32%)	   with	   laboratory	   confirmed	   invasive	   GAS	   infection,	   some	   of	  
which	   will	   undoubtedly	   have	   been	   admitted	   to	   hospital	   because	   of	   that	   invasive	   GAS	   infection.	  
Although	  exclusion	  of	  these	  cases	  is	  logical	  when	  wishing	  to	  reduce	  the	  risk	  of	  overestimating	  costs,	  
such	   a	   step	   is	   reliant	   on	   accurate	   and	   relevant	   coding	   within	   HES	   and	   the	   a	   priori	   selection	   of	  
appropriate	  invasive	  GAS	  infection	  defining	  codes.	  Although	  we	  have	  been	  thorough	  in	  our	  reduction	  
of	  error	  from	  the	  latter,	  we	  have	  not	  determined	  the	  influence	  of	  inaccurate	  HES	  codes	  [29]	  or	  the	  
dominance	  of	  other	  conditions	  with	  regard	  to	  diagnosis.	  Ultimately,	  these	  cases	  either	  reflect	  those	  
where	  treatment	  for	  invasive	  GAS	  infection	  truly	  did	  not	  dominant	  hospital	  care	  or	  where	  the	  nature	  
of	  HES	  coding	  has	  obscured	  direct	  recognition	  of	  that	  care.	  	  
We	   are	   not	   aware	   of	   any	   published	   studies	   which	   have	   applied	   this	   case	   level	   methodology	   to	  
comparative	   invasive	  bacterial	   infections	   in	  England.	  A	  small	  study	  published	  over	  20	  years	  ago	  for	  
invasive	  Haemophilus	   influenzae	   infection	  found	  costs	  for	  hospital	  admissions	  using	  base	  reference	  
costs	  (£2300	  without	  critical	  care,	  £4300	  with)	  [30]	  to	  be	  not	  dissimilar	  to	  those	  found	  here,	  but	  this	  
comparison	   does	   not	   consider	   inflation.	   Costs	   of	   hospital	   admissions	   for	   invasive	   pneumococcal	  
infection	   (£903–£1547,	   depending	   on	   clinical	   presentation)	   [20]	   and	   invasive	   meningococcal	  
infection	  (£2337)	  [31]	  have	  been	  produced	  for	  cost-­‐effectiveness	  estimates	  and	  are	  also	  not	  widely	  
different	   from	   our	   estimates	   for	   invasive	   GAS.	   However,	   the	   lack	   of	   a	   case	   list	   independent	   to	  
hospital	   admission	   data	   prevents	   such	   aggregate	   studies	   accounting	   for	   variance	   in	   costs	   at	   an	  
individual	   level.	  Moreover,	   the	  clinical	  diversity	  and	  distribution	  of	   co-­‐morbidities	   for	   invasive	  GAS	  
infection	  restricts	  the	  application	  of	  definitions	  on	  the	  basis	  of	  diagnostic	  coding.	  Diagnoses	  made	  on	  
admission	   to	   hospital	  may	   involve	   recording	   of	   underlying	   conditions	   and	   risk	   factors	   for	   invasive	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GAS	   infection	   such	   as	   cancer	   and	   chronic	   diseases	   [8]	   which	   do	   not	   preclude	   the	   presence	  
(recognised	  or	  not)	  of	  a	  concomitant	  invasive	  GAS	  infection.	  This	  situation	  is	  further	  complicated	  for	  
secondary	   hospital	   admissions	   where	   there	   is	   the	   combination	   of	   invasive	   GAS	   infection,	   post-­‐
operative	   care,	   post-­‐infection	   care	   and	   post-­‐infection	   sequelae.	   For	   this	   reason,	   we	   adopted	   a	  
pragmatic	   approach	   to	   defining	   secondary	   admissions,	   applying	   a	   simple	   definition	   with	   the	  
acceptance	   that	   both	   the	   inclusion	  of	   unrelated	   admissions	   and	   censoring	  of	   invasive	  GAS-­‐related	  
ones	  were	  likely.	  Nevertheless,	  we	  feel	  that	  the	  majority	  of	  re-­‐admissions	  as	  a	  direct	  consequence	  of	  
a	  previous	  invasive	  GAS	  infection	  will	  occur	  within	  30	  days	  of	  the	  end	  of	  the	  primary	  admission.	  	  
Critical	  care	  resources	  made	  up	  a	  substantial	  contribution	  to	  our	  estimates	  of	  costs,	  upon	  which	  we	  
have	  made	  three	  assumptions.	  Firstly,	  we	  have	  made	  a	  fixed	  adjustment	  based	  on	  the	  assumption	  
that	  the	  HES-­‐based	  methodology	  has	  under	  ascertained	  critical	  care	  cases	  by	  a	  factor	  of	  four	  (due	  to	  
the	  use	  of	  a	  dedicated	  separate	  data	  stream	  for	  critical	  care	  admissions).	  This	  assumption	   is	  based	  
on	  published	  data	  for	  England	  [2,	  27],	  Australia	  [4],	  Denmark	  [32]	  and	  New	  Zealand	  [6].	  Whilst	  the	  
principle	   and	  magnitude	  of	   the	  adjustment	  are	   reasonable,	  we	  were	  unable	   to	   assess	   the	   level	  of	  
adjustment	   separately	   for	   each	   costing	   group.	   As	   such,	   these	   subgroup-­‐specific	   critical	   care	  
estimates	  are	  not	   likely	  to	  be	  robust.	  Secondly,	  we	  have	  assumed	  that	  the	  duration	  of	  critical	  care	  
episodes	  when	  recorded	  in	  HES	  is	  an	  accurate	  duration	  of	  critical	  care	  provided	  generally	  for	  invasive	  
GAS	  patients.	  As	   the	  median	  duration	  of	   these	  episodes	   (4	  days)	  appears	   to	  be	  broadly	  consistent	  
with	  that	  reported	  in	  Canada	  [33]	  and	  New	  Zealand	  [6],	  this	  would	  appear	  to	  be	  sensible.	  Thirdly,	  we	  
have	  based	  costs	  on	  support	  for	  three	  organs	  during	  critical	  care,	  which	  is	  validated	  by	  limited	  data	  
from	   our	   study	   and	   elsewhere	   [33].	   After	   the	   discontinuation	   of	   the	   ACP	   dataset,	   critical	   care	  
episodes	  are	  not	  routinely	  or	  consistently	  recorded	  in	  HES	  and	  a	  separate	  dataset	  now	  exists	  for	  that	  
purpose	  [34].	  
The	   total	   economic	   burden	   of	   invasive	   GAS	   infections	   will	   of	   course	   include	   general	   practice	  
consultations/other	  primary	  care	  costs	  and	  further	  costs	  associated	  with	   lost	  working	  days	  and	  life	  
years.	   The	   latter	  will	   be	   substantial	   for	   invasive	  GAS	   infection	  given	   the	  associated	  high	  mortality,	  
although	  for	  these	  cases	  healthcare	  costs	  will	  ultimately	  be	  reduced	  as	  death	  tends	  to	  occur	  rapidly	  
after	   diagnosis	   [7].	  We	  have	   limited	   our	   study	   to	   invasive	   infections	   caused	   by	  GAS	   and	  have	   not	  
attempted	   to	   estimate	   the	   financial	   costs	   associated	   with	   the	   management	   of	   less	   severe	   GAS	  
infections	  by	  primary	  care	  services	  or	  those	  costs	  associated	  with	  public	  health	  actions,	  such	  as	  the	  
management	   of	   outbreaks	   and	   close	   contacts	   of	   cases.	   All	   of	   these	   costs	   are	   to	   our	   knowledge	  
unknown	  yet	  vital	  should	  a	   full	  estimate	  of	  cost-­‐effectiveness	   for	  vaccination	  be	  required.	   Invasive	  
GAS	  infection	  has	  a	  high	  mortality	  rate	  and	  affects	  all	  ages,	  including	  the	  otherwise	  healthy	  [2],	  and	  
the	  burden	  is	  likely	  to	  be	  considerable.	  Despite	  the	  modest	  progress	  in	  vaccine	  development	  for	  GAS	  
infection	  [12],	  it	  seems	  likely	  that	  a	  commitment	  to	  development	  of	  a	  vaccine	  for	  GAS	  will	  continue	  
[35].	  The	  costing	  estimates	  from	  this	  study	  will	  contribute	  towards	  a	  full	  cost-­‐effectiveness	  estimate	  
as	   and	  when	   it	   is	   undertaken,	   but	   for	   now	   provides	   valuable	   knowledge	   of	   the	   financial	   costs	   of	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